With favorable results in hand from a phase IIa pharmacokinetic (PK) study with its Parkinson's disease (PD) treatments, Neuroderm Ltd. is planning a head-to-head trial against Abbvie Inc.'s Duodopa – cleared in Europe, pending in the U.S. – next year, Oded Lieberman, CEO of the Rehovot, Israel-based firm, told BioWorld Today